Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.40 |
| ▸ | DRD4 | P21917 | 4/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482629 | 0.90 | F2 (0.55) | F2POLBHDAC6DRD4HDAC1 | |
| Hydrochloric Acid SCHEMBL6474728 | 0.90 | F2 (0.55) | F2POLBHDAC6DRD4HDAC1 | |
| SCHEMBL6475172 | 0.87 | POLB (0.45) | F2POLBHDAC6DRD4HDAC1 | |
| SCHEMBL6475903 | 0.87 | F2 (0.45) | F2POLBHDAC6DRD4HDAC1 | |
| SCHEMBL6484203 | 0.85 | F2 (0.44) | F2POLBHDAC6DRD4HDAC1 | |
| SCHEMBL6480918 | 0.84 | POLB (0.43) | F2POLBHDAC6DRD4HDAC1 | |
| SCHEMBL6476545 | 0.83 | F2 (0.50) | F2HDAC1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6474788 | 0.81 | F2 (0.55) | F2HDAC6HDAC1NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL6485385 | 0.81 | F2 (0.49) | F2HDAC6HDAC1NPC1RAB9A | |
| SCHEMBL6475905 | 0.81 | F2 (0.41) | F2POLBHDAC6HDAC1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6855713-B2 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-02-15 | — | — | US | disclosed |
| US-20030130265-A1 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130265-A1 | Benzimidazole derivatives, a process for their manufacture and use as a medicine | TPSAB1, PRSS3, TPSD1 | F2 101/4885POLB 2209/4885HDAC6 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.